Mthokozisi Bongani Nxumalo

Mr. Mthokozisi Bongani Nxumalo


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
MNMthokozisi Bongani Nxumalo
Mthokozisi Bongani Nxumalo
NNNosipho Ntanzi
Nosipho Ntanzi
HKHezekiel Kumalo
Hezekiel Kumalo
RKRene R. Khan
Rene R. Khan
Background/Objectives: Diabetes often goes undiagnosed, with 60% of people in Africa unaware of their condition. Type 2 diabetes mellitus (T2DM) is associated with insulin resistance and is treated with metformin, despite the undesirable side effects. Medicinal plants with therapeutic potential, such as Carica papaya, have shown promising anti-diabetic properties. This study explored the role of C. papaya leaf and root extracts compared to metformin in reducing hyperglycaemia-induced oxidative stress and their impact on liver function using HepG2 as a reference. Methods: The cytotoxicity was assessed through the MTT assay. At the same time, glucose uptake and metabolism (ATP and ∆Ψm) in HepG2 cells treated with C. papaya aqueous leaf and root extract were evaluated using a luminometry assay. Additionally, antioxidant properties (SOD2, GPx1, GSH, and Nrf2) were measured using qPCR and Western blot following the detection of MDA, NO, and iNOS, indicators of free radicals. Results: The MTT assay showed that C. papaya extracts did not exhibit toxicity in HepG2 cells and enhanced glucose uptake compared to the hyperglycaemic control (HGC) and metformin. The glucose levels in C. papaya-treated cells increased ATP production (p < 0.05), while the ∆Ψm was significantly increased in HGR1000-treated cells (p < 0.05). Furthermore, C. papaya leaf extract upregulated GPx1 (p < 0.05), GSH, and Nrf2 gene (p < 0.05), while SOD2 and Nrf2 proteins were reduced (p > 0.05), ultimately lowering ROS (p > 0.05). Contrarily, the root extract stimulated SOD2 (p > 0.05), GPx1 (p < 0.05), and GSH levels (p < 0.05), reducing Nrf2 gene and protein expression (p < 0.05) and resulting in high MDA levels (p < 0.05). Additionally, the extracts elevated NO levels and iNOS expression (p < 0.05), suggesting potential RNS activation. Conclusion: Taken together, the leaf extract stimulated glucose metabolism and triggered ROS production, producing a strong antioxidant response that was more effective than the root extract and metformin. However, the root extract, particularly at high concentrations, was less effective at neutralising free radicals as it did not stimulate Nrf2 production, but it did maintain elevated levels of SOD2, GSH, and GPx1 antioxidants.

22 August 2025 in Food Bioscience
Verified
Journal Article
Open access
MNMthokozisi Bongani Nxumalo
Mthokozisi Bongani Nxumalo
NNNosipho Ntanzi
Nosipho Ntanzi
FTFave Yohanna Tata
Fave Yohanna Tata
HKHezekiel Mathambo Kumalo
Hezekiel Mathambo Kumalo
RKRene Bernadette Khan
Rene Bernadette Khan

13 February 2026 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
MNMthokozisi Bongani Nxumalo
Mthokozisi Bongani Nxumalo
RKRene Bernadette Khan
Rene Bernadette Khan
NNNosipho Ntanzi
Nosipho Ntanzi
FTFave Yohanna Tata
Fave Yohanna Tata
HKHezekiel Mathambo Kumalo
Hezekiel Mathambo Kumalo
Type 2 diabetes mellitus (T2DM) is characterised by impaired glucose homeostasis arising from insulin resistance and inadequate insulin action in peripheral tissues. Carica papaya has been reported to exert antidiabetic effects; however, its molecular mechanisms in hepatic and skeletal muscle cells under hyperglycemic conditions remain incompletely understood. This study investigated the effects of C. papaya leaf and root extracts on glucose uptake and insulin-related signalling pathways in HepG2 hepatocytes and C2C12 myotubes. Enzyme inhibition assays were used to assess α-amylase and α-glucosidase activity, while protein and gene expression of key components of the MAPK and PI3K/AKT pathways were evaluated using Western blotting and qPCR. C. papaya extracts significantly inhibited α-amylase activity (p < 0.05), with a non-significant inhibitory trend observed for α-glucosidase, suggesting reduced glucose availability under hyperglycemic conditions. In both HepG2 and C2C12 cells, C. papaya attenuated MAPK signalling through suppression of Erk1/2 and p38 MAPK, while JNK inhibition was observed exclusively in HepG2 cells (p < 0.05). In HepG2 cells, AKT and GLUT2 gene expression remained unchanged; however, AMPKα and IRS-1 were significantly upregulated, indicating enhanced glucose uptake potential despite a concomitant reduction in glycogen synthase expression (p < 0.05). In contrast, C2C12 myotubes exhibited enhanced insulin signalling characterised by increased phosphorylated IRS-1, AKT activation, and elevated glycogen synthase expression, supporting improved glucose uptake and storage (p < 0.05). Collectively, these findings demonstrate that C. papaya extracts mitigate hyperglycemia-induced insulin resistance by suppressing MAPK signalling and enhancing glucose uptake through distinct, cell-specific mechanisms in hepatic and skeletal muscle cells.

8 June 2026 in Health Sciences Review
Verified
Journal Article
Open access
MNMthokozisi Bongani Nxumalo
Mthokozisi Bongani Nxumalo
HKHezekiel M. Kumalo
Hezekiel M. Kumalo
LMLebogang Maruma
Lebogang Maruma
FTFave Y. Tata
Fave Y. Tata
NNNosipho Ntanzi
Nosipho Ntanzi
RKRene B. Khan
Rene B. Khan

Verified
Journal Article
Open access
PDF file
FTFave Yohanna Tata
Fave Yohanna Tata
MNMthokozisi Bongani Nxumalo
Mthokozisi Bongani Nxumalo
NNNosipho Ntanzi
Nosipho Ntanzi
AMAganze Gloire-Aimé Mushebenge
Aganze Gloire-Aimé Mushebenge
RKRene R. Khan
Rene R. Khan
HKHezekiel Kumalo
Hezekiel Kumalo
The convergence of metabolic dysfunction and infectious diseases has become increasingly evident, particularly during the COVID-19 pandemic. AMP-activated protein kinase (AMPK) and angiotensin-converting enzyme 2 (ACE2) emerge as pivotal molecular regulators linking metabolic homeostasis, endothelial integrity, immune modulation, and viral pathogenesis. Metabolic diseases such as diabetes, obesity, and non-alcoholic fatty liver disease are marked by insulin resistance, chronic inflammation, oxidative stress, and endothelial dysfunction, collectively increasing susceptibility to severe viral infections and outcomes. This review examines experimental, computational, and translational evidence exploring the interplay between AMPK and ACE2, focusing on metabolic, vascular, and inflammatory pathways relevant to viral infections. Recent findings show a bidirectional functional relationship between AMPK and ACE2, where AMPK phosphorylation supports ACE2 expression and function, and ACE2 signaling reciprocally enhances AMPK activity, forming a protective metabolic–vascular loop. Disruption of this axis, particularly through SARS-CoV-2-induced ACE2 degradation, exacerbates metabolic deterioration, vascular damage, and exaggerated inflammatory responses. Preclinical and in silico studies show that pharmacological AMPK activators, including metformin and bioactive flavonoids, demonstrate pleiotropic metabolic, anti-inflammatory, endothelial protective, and potential antiviral activities, hinting at the therapeutic potential of modulating the AMPK-ACE2 axis, despite the limited clinical application of flavonoids. The AMPK-ACE2 axis represents an important molecular link between metabolic regulation, renovascular health, and immune defense mechanisms. This evaluation connects AMPK and ACE2 from isolated signaling nodes into a coordinated pharmacological axis with implications for interventions in cardiometabolic and viral diseases. Future research should prioritize mechanistic validation and conduct integrated experimental and clinical investigations to establish AMPK-ACE2 co-targeting as a viable therapeutic strategy for mitigating cardiometabolic disease burden and enhancing resilience against viral infections.